ADR 851

Drug Profile

ADR 851

Latest Information Update: 06 Oct 2006

Price : $50

At a glance

  • Originator Adria; Pfizer
  • Developer Adria
  • Class Antiemetics; Antipsychotics; Anxiolytics
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Anxiety disorders; Nausea and vomiting

Most Recent Events

  • 02 Feb 2001 Profile reviewed but no significant changes made
  • 23 Jul 1996 No-Development-Reported for Anxiety disorders in USA (IV)
  • 23 Jul 1996 No-Development-Reported for Emesis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top